© Diamyd Medical

Building a diabetes major

Diabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.

Hannelius holds a PhD in molecular biology from the Karolinska Institute and an MBA from the Stockholm School of Economics. Since November 2015, he held the position of Business Development Manager at Diamyd. Prior to that, Hannelius held the same position at Swiss Labtronica SA. In 2011, he founded the life science consultancy provider Aneega AB. As CEO and President, he will focus on building up Diamyd as a “significant” diabetes company. He takes over from Anders Essen-Möller, who was interim CEO.